Sectors

QNCX
Quince Therapeutics, Inc.
32.66
2 x 23.62
2 x 41.26
bid
ask
-
1.09
3.23%
02:03 PM
timesize
Ytd-95.13%
1y-89.79%
32.24
day range
34.04
15.10
52 week range
910.00
Open34.04Prev Close33.75Low32.24High34.04Mkt Cap33.22M
Vol29.36KAvg Vol31.87KEPS-210.84P/EN/AForward P/E-5.68
Beta1.36Short Ratio2.27Inst. Own25.53%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-1250-d Avg23.88200-d Avg183.351yr Est9.00
Income Statement
Operating Expenses79.78M
Research and Development Expense5.46M
Selling, General and Administrative Expense16.63M
Operating Income-79.78M
Income Tax Expense75.00K
Net Income-75.49M
Net Income Common Stock-75.49M
Net Income Common Stock (USD)-75.49M
Consolidated Income-75.49M
Earnings per Basic Share-12.31
Earnings per Basic Share (USD)-12.31
Earnings per Diluted Share-12.31
Earning Before Interest & Taxes (EBIT)-75.41M
Earning Before Interest & Taxes (USD)-75.41M
Weighted Average Shares6.13M
Weighted Average Shares Diluted6.13M
Balance Sheet
Cash and Equivalents115.98M
Cash and Equivalents (USD)115.98M
Current Assets123.41M
Property, Plant & Equipment Net506.00K
Total Assets124.00M
Current Liabilities8.50M
Total Liabilities15.51M
Accumulated Retained Earnings (Deficit)-500.03M
Accumulated Other Comprehensive Income4.26M
Shareholders Equity-35.32M
Shareholders Equity (USD)-35.32M
Assets Non-Current584.00K
Liabilities Non-Current7.01M
Trade and Non-Trade Payables4.64M
Cash Flow
Depreciation, Amortization & Accretion41.00K
Net Cash Flow from Financing108.93M
Net Cash Flow / Change in Cash & Cash Equivalents97.82M
Net Cash Flow - Business Acquisitions and Disposals8.00M
Issuance (Purchase) of Equity Shares5.29M
Net Cash Flow from Investing8.00M
Net Cash Flow from Operations-18.89M
Effect of Exchange Rate Changes on Cash -229.00K
Share Based Compensation12.09M